Top member reports
Consensus community valuation
The consensus valuation is for members only and has been removed from this chart. Click for membership options.
Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Business Model/Strategy
stale
Added 3 years ago

I just wonder out loud about how a manufacturing deal would look financially for IDT. 

Disclosure that I do have it in my straw portfolio but my immediate questions would be as follows. 

Are they going to develop their own mRNA vaccines which would be higher risk and much higher reward or are they piggybacking other companies to provide greater on shore supply? 

On the second note how would this look financially, they have a facility they are able to make fit for purpose but with vaccines being in excess of 18months+ away it sounds like the funds would be government grant to get to manufacturing point (designed to cover cost and not yeild profit) followed by manufacturing and onselling agreements. 

My personal opinion at this stage is that they have a long and expensive road ahead in competition with some big established players such as CSL who may be better equipped to both develop and manufacture NEW mRNA vaccines.

Would love to hear counter arguements to this! 

Read More
#Business Model/Strategy
stale
Added 3 years ago

@platanos.

no comment on IDT but here is great podcast on where mRNA could heading. As you rightly point, out it will be huge.

I hold Pfizer on that basis, and the likely upside from shrt term COVID stuff.

Read More